Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
05 janv. 2023 07h00 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
29 déc. 2022 11h31 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
28 déc. 2022 08h30 HE
|
Unicycive Therapeutics, Inc.
Renazorb demonstrates pharmacodynamic bioequivalence to Fosrenol Renazorb’s enhanced product profile features reduced pill burden and small, swallowable tablets, which may improve patient compliance...
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
22 déc. 2022 07h00 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease,...
Unicycive to Participate in Upcoming Investor Conferences
28 nov. 2022 07h00 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs,...
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy
21 nov. 2022 07h00 HE
|
Unicycive Therapeutics, Inc.
Treatment with UNI-494 improved contrast vision in animal models of geographic atrophy (GA) GA is an advanced form of Age-related Macular Degeneration (AMD) and there are currently no FDA-approved...
Unicycive Announces Third Quarter Financial Results and Provides Business Update
14 nov. 2022 07h00 HE
|
Unicycive Therapeutics, Inc.
Topline results by year-end as enrollment completed for pivotal bioequivalence study of RENAZORB™ (lanthanum dioxycarbonate), an investigational phosphate binder for the treatment of hyperphosphatemia...
Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
10 nov. 2022 07h00 HE
|
Unicycive Therapeutics, Inc.
Topline Data Expected by Year End 2022 On Track to File the NDA in 2023 LOS ALTOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage...
Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology’s Kidney Week 2022
26 oct. 2022 08h04 HE
|
Unicycive Therapeutics, Inc.
Multiple Data Presentations Support the Company’s Pipeline of Innovative Product Candidates aimed at Improving the Quality-of-Life for Patients Battling Kidney Disease Independently Hosted Key...
Unicycive Therapeutics to Present at Roth Inaugural Healthcare Opportunities Conference
29 sept. 2022 07h00 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...